Pulmonary Hypertension in Systemic Sclerosis

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 1, 2011, Pages 19-37

  Chatterjee, Soumya ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Investigation; Pathogenesis; Pathology; Prognosis; Pulmonary arterial hypertension; Pulmonary hypertension; Pulmonary veno occlusive disease; Scleroderma; Systemic sclerosis; Treatment

Indexed keywords

ADENOSINE; AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

ANTICOAGULANT THERAPY; ARTICLE; BACKACHE; BLALOCK HANLON OPERATION; BLEEDING; CLINICAL CLASSIFICATION; CONTINUOUS INFUSION; DIARRHEA; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; EXERCISE INDUCED PULMONARY HYPERTENSION; EXERCISE TEST; FORCED VITAL CAPACITY; FORWARD HEART FAILURE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HISTOPATHOLOGY; HUMAN; INJECTION SITE PAIN; INTERSTITIAL LUNG DISEASE; JAW PAIN; LIVER TOXICITY; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG TRANSPLANTATION; NAUSEA; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VENO-OCCLUSIVE DISEASE; RAYNAUD PHENOMENON; SCLERODERMA; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC SCLEROSIS; THORAX PAIN; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION;

EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; MEDLINE; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 80051469543     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.08.004     Document Type: Article

References (124)

1. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S43-S54.
2. Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., Kimmel S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123(2):344-350.
3. Fisher M.R., Mathai S.C., Champion H.C., Girgis R.E., Housten-Harris T., Hummers L., et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006, 54(9):3043-3050.
4. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52(12):3792-3800.
5. Mukerjee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62(11):1088-1093.
6. Phung S., Strange G., Chung L.P., Leong J., Dalton B., Roddy J., et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009, 39(10):682-691.
7. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66(7):940-944.
8. Wigley F.M., Lima J.A., Mayes M., McLain D., Chapin J.L., Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005, 52(7):2125-2132.
9. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107(2):216-223.
10. Badesch D.B., Champion H.C., Sanchez M.A., Hoeper M.M., Loyd J.E., Manes A., et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S55-S66.
11. Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007, 96(8):527-541.
12. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34(6):1219-1263.
13. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48(2):516-522.
14. Schachna L., Wigley F.M., Chang B., White B., Wise R.A., Gelber A.C. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003, 124(6):2098-2104.
15. Hachulla E., Launay D., Mouthon L., Sitbon O., Berezne A., Guillevin L., et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. Chest 2009, 136(5):1211-1219.
16. Denton C.P., Cailes J.B., Phillips G.D., Wells A.U., Black C.M., Bois R.M. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997, 36(2):239-243.
17. Fischer A., Swigris J.J., Groshong S.D., Cool C.D., Sahin H., Lynch D.A., et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008, 134(3):6015.
18. Denton C.P., Black C.M. Pulmonary fibrosis and pulmonary vascular involvement in systemic sclerosis: 9b. Pulmonary vascular involvement in systemic sclerosis. Systemic sclerosis 2004, 184-193. Lippincott Williams & Wilkins, Philadelphia (PA). P.J. Clements, D.E. Furst (Eds.).
19. Goldberg A. Pulmonary arterial hypertension in connective tissue diseases. Cardiol Rev 2010, 18(2):85-88.
20. Kuwana M., Okazaki Y., Yasuoka H., Kawakami Y., Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364(9434):603-610.
21. Yousem S.A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990, 21(5):467-474.
22. al Sabbagh M.R., Steen V.D., Zee B.C., Nalesnik M., Trostle D.C., Bedetti C.D., et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989, 16(8):1038-1042.
23. Ferri C., Di B.V., Martini A., Giorgi D., Storino F.A., Bianchi M., et al. Heart involvement in systemic sclerosis: an ultrasonic tissue characterisation study. Ann Rheum Dis 1998, 57(5):296-302.
24. Meune C., Avouac J., Wahbi K., Cabanes L., Wipff J., Mouthon L., et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008, 58(6):1803-1809.
25. Dimitroulas T., Giannakoulas G., Papadopoulou K., Karvounis H., Dimitroula H., Koliakos G., et al. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 2010, (in press).
26. Giunta A., Tirri E., Maione S., Cangianiello S., Mele A., De Luca A., et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000, 59(2):94-98.
27. Bezante G.P., Rollando D., Sessarego M., Panico N., Setti M., Filaci G., et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007, 34(12):2431-2437.
28. Hachulla A.L., Launay D., Gaxotte V., de Groote P., Lamblin N., Devos P., et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009, 68(12):1878-1884.
29. Fernandes F., Ramires F.J., Arteaga E., Ianni B.M., Bonfa E.S., Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003, 9(4):311-317.
30. de Groote P., Gressin V., Hachulla E., Carpentier P., Guillevin L., Kahan A., et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008, 67(1):31-36.
31. Candell-Riera J., Armadans-Gil L., Simeon C.P., Castell-Conesa J., Fonollosa-Pla V., Garcia-del-Castillo H., et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996, 39(7):1138-1145.
32. Owens G.R., Follansbee W.P. Cardiopulmonary manifestations of systemic sclerosis. Chest 1987, 91(1):118-127.
33. Overbeek M.J., Lankhaar J.W., Westerhof N., Voskuyl A.E., Boonstra A., Bronzwaer J.G., et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008, 31(6):1160-1166.
34. D'Angelo W.A., Fries J.F., Masi A.T., Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46(3):428-440.
35. Norton W.L., Nardo J.M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970, 73(2):317-324.
36. Cool C.D., Kennedy D., Voelkel N.F., Tuder R.M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997, 28(4):434-442.
37. Overbeek M.J., Vonk M.C., Boonstra A., Voskuyl A.E., Vonk-Noordegraaf A., Smit E.F., et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009, 34(2):371-379.
38. Dorfmuller P., Montani D., Humbert M. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2010, 35(1):6-8.
39. Morassut P.A., Walley V.M., Smith C.D. Pulmonary veno-occlusive disease and the CREST variant of scleroderma. Can J Cardiol 1992, 8(10):1055-1058.
40. Saito A., Takizawa H., Ito K., Yamamoto K., Oka T. A case of pulmonary veno-occlusive disease associated with systemic sclerosis. Respirology 2003, 8(3):383-385.
41. Johnson S.R., Patsios D., Hwang D.M., Granton J.T. Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006, 33(11):2347-2350.
42. Palmer S.M., Robinson L.J., Wang A., Gossage J.R., Bashore T., Tapson V.F. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998, 113(1):237-240.
43. Dorfmuller P., Humbert M., Perros F., Sanchez O., Simonneau G., Muller K.M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38(6):893-902.
44. Edelman J.D. Clinical presentation, differential diagnosis, and vasodilator testing of pulmonary hypertension. Semin Cardiothorac Vasc Anesth 2007, 11(2):110-118.
45. Condliffe R., Kiely D.G., Peacock A.J., Corris P.A., Gibbs J.S., Vrapi F., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179(2):151-157.
46. Mathai S.C., Hummers L.K., Champion H.C., Wigley F.M., Zaiman A., Hassoun P.M., et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009, 60(2):569-577.
47. Tolle J.J., Waxman A.B., Van Horn T.L., Pappagianopoulos P.P., Systrom D.M. Exercise-induced pulmonary arterial hypertension. Circulation 2008, 118(21):2183-2189.
48. Steen V., Chou M., Shanmugam V., Mathias M., Kuru T., Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008, 134(1):146-151.
49. Callejas-Rubio J.L., Moreno-Escobar E., de la Fuente P.M., Perez L.L., Fernandez R.R., Sanchez-Cano D., et al. Prevalence of exercise pulmonary arterial hypertension in scleroderma. J Rheumatol 2008, 35(9):1812-1816.
50. Kovacs G., Berghold A., Scheidl S., Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009, 34(4):888-894.
51. Naeije R., Melot C., Niset G., Delcroix M., Wagner P.D. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. J Appl Physiol 1993, 74(4):1666-1671.
52. McLaughlin V.V., Presberg K.W., Doyle R.L., Abman S.H., McCrory D.C., Fortin T., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(Suppl 1):78S-92S.
53. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115(5):343-349.
54. Sandoval J., Bauerle O., Palomar A., Gomez A., Martinez-Guerra M.L., Beltran M., et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994, 89(4):1733-1744.
55. Okada O., Tanabe N., Yasuda J., Yoshida Y., Katoh K., Yamamoto T., et al. Prediction of life expectancy in patients with primary pulmonary hypertension. A retrospective nationwide survey from 1980-1990. Intern Med 1999, 38(1):12-16.
56. Rajasekhar D., Balakrishnan K.G., Venkitachalam C.G., Tharakan J.A., Titus T., Subramanian R., et al. Primary pulmonary hypertension: natural history and prognostic factors. Indian Heart J 1994, 46(3):165-170.
57. Koh E.T., Lee P., Gladman D.D., Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996, 35(10):989-993.
58. Coghlan J.G., Handler C. Connective tissue associated pulmonary arterial hypertension. Lupus 2006, 15(3):138-142.
59. Launay D., Sitbon O., Le Pavec J., Savale L., Tcherakian C., Yaici A., et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010, 49(3):490-500.
60. McLaughlin V., Humbert M., Coghlan G., Nash P., Steen V., et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii25-iii31.
61. Proudman S.M., Stevens W.M., Sahhar J., Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007, 37(7):485-494.
62. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161(2 Pt. 1):487-492.
63. Rasekaba T., Lee A.L., Naughton M.T., Williams T.J., Holland A.E. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J 2009, 39(8):495-501.
64. Impens A.J., Wangkaew S., Seibold J.R. The 6-minute walk test in scleroderma-how measuring everything measures nothing. Rheumatology (Oxford) 2008, 47(Suppl 5):v68-v69.
65. Buch M.H., Denton C.P., Furst D.E., Guillevin L., Rubin L.J., Wells A.U., et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007, 66(2):169-173.
66. Garin M.C., Highland K.B., Silver R.M., Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009, 36(2):330-336.
67. Pamidi S., Mehta S. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts?. J Rheumatol 2009, 36(2):216-218.
68. Schoindre Y., Meune C., Dinh-Xuan A.T., Avouac J., Kahan A., Allanore Y. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009, 36(7):1481-1485.
69. Mathai S.C., Hassoun P.M. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol 2009, 21(6):642-648.
70. Villalba W.O., Sampaio-Barros P.D., Pereira M.C., Cerqueira E.M., Leme C.A., Marques-Neto J.F., et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007, 131(1):217-222.
71. Dimitroulas T., Giannakoulas G., Karvounis H., Gatzoulis M.A., Settas L. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2010, 39(4):278-284.
72. Allanore Y., Meune C. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009, 27(3 Suppl 54):59-63.
73. Mukerjee D., Yap L.B., Holmes A.M., Nair D., Ayrton P., Black C.M., et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003, 97(11):1230-1236.
74. Warwick G., Thomas P.S., Yates D.H. Biomarkers in pulmonary hypertension. Eur Respir J 2008, 32(2):503-512.
75. Montagnana M., Lippi G., Volpe A., Salvagno G.L., Biasi D., Caramaschi P., et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006, 39(9):913-917.
76. Allanore Y., Wahbi K., Borderie D., Weber S., Kahan A., Meune C. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?. Ann Rheum Dis 2009, 68(12):1885-1889.
77. Allanore Y., Borderie D., Meune C., Cabanes L., Weber S., Ekindjian O.G., et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003, 48(12):3503-3508.
78. Allanore Y., Borderie D., Avouac J., Zerkak D., Meune C., Hachulla E., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58(1):284-291.
79. Williams M.H., Handler C.E., Akram R., Smith C.J., Das C., Smee J., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27(12):1485-1494.
80. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002, 40(5):976-982.
81. Das S.R., Drazner M.H., Dries D.L., Vega G.L., Stanek H.G., Abdullah S.M., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005, 112(14):2163-2168.
82. Leuchte H.H., El Nounou M., Tuerpe J.C., Hartmann B., Baumgartner R.A., Vogeser M., et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007, 131(2):402-409.
83. Mathai S.C., Bueso M., Hummers L.K., Boyce D., Lechtzin N., Le Pavec J., et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010, 35(1):95-104.
84. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111(23):3105-3111.
85. Ishikawa H., Iwakiri K., Sugiura T., Kobayashi M. Effect of nifedipine administration (10 mg) on esophageal acid exposure time. J Gastroenterol 2000, 35(1):43-46.
86. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007, 131(6):1917-1928.
87. Coghlan J.G., Handler C. Connective tissue associated pulmonary arterial hypertension. Lupus 2006, 15(3):138-142.
88. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians. American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(16):2250-2294.
89. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984, 70(4):580-587.
90. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327(2):76-81.
91. Minai O.A., Budev M.M. Treating pulmonary arterial hypertension: cautious hope in a deadly disease. Cleve Clin J Med 2007, 74(11):789-800. 802.
92. Srock K., Kerr L.D., Poon M., Fallon J.T. Refractory pulmonary hypertension in a lupus patient with occult pulmonary vasculitis. J Clin Rheumatol 2003, 9(4):263-266.
93. Sanchez O., Sitbon O., Jais X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130(1):182-189.
94. Park Y.W., Woo H., Jeong Y.Y., Lee J.H., Park J.J., Lee S.S. Association of nodular regenerative hyperplasia of the liver with porto-pulmonary hypertension in a patient with systemic lupus erythematosus. Lupus 2006, 15(10):686-688.
95. Chung L., Liu J., Parsons L., Hassoun P.M., McGoon M., Badesch D., et al. Characterization of connective tissue disease associated pulmonary arterial hypertension from the REVEAL registry: identifying systemic sclerosis as a unique phenotype. Chest 2010, (in press).
96. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334(5):296-302.
97. Menon N., McAlpine L., Peacock A.J., Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis Rheum 1998, 41(3):466-469.
98. Humbert M., Sanchez O., Fartoukh M., Jagot J.L., Sitbon O., Simonneau G. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). Chest 1998, 114(Suppl 1):80S-82S.
99. Klings E.S., Hill N.S., Ieong M.H., Simms R.W., Korn J.H., Farber H.W. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999, 42(12):2638-2645.
100. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132(6):425-434.
101. Fagan K.A., Badesch D.B. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002, 45(3):225-234.
102. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165(6):800-804.
103. Oudiz R.J., Schilz R.J., Barst R.J., Galie N., Rich S., Rubin L.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004, 126(2):420-427.
104. Laliberte K., Arneson C., Jeffs R., Hunt T., Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004, 44(2):209-214.
105. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., Benza R.L., Widlitz A.C., Krichman A., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006, 129(3):683-688.
106. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347(5):322-329.
107. Launay D., Hachulla E., Hatron P.Y., Goullard L., Onimus T., Robin S., et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001, 28(10):2252-2256.
108. Matsukawa Y., Saito O., Aoki M., Abe M., Nishinarita S., Sawada S., et al. Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins Leukot Essent Fatty Acids 2002, 67(1):45-49.
109. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358(9288):1119-1123.
110. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12):896-903.
111. Cozzi F., Montisci R., Marotta H., Bobbo F., Durigon N., Ruscazio M., et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006, 36(Suppl 3):49-53.
112. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006, 47(10):2049-2056.
113. Galie N., Badesch D., Oudiz R., Simonneau G., McGoon M.D., Keogh A.M., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46(3):529-535.
114. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353(20):2148-2157.
115. Badesch D.B., Hill N.S., Burgess G., Rubin L.J., Barst R.J., Galie N., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007, 34(12):2417-2422.
116. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22):2894-2903.
117. Galie N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30(4):394-403.
118. Ramirez A., Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004, 3(6):339-352.
119. Barst R.J. Role of atrial septostomy in the treatment of pulmonary vascular disease. Thorax 2000, 55(2):95-96.
120. Allcock R.J., O'Sullivan J.J., Corris P.A. Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. Arthritis Rheum 2001, 44(7):1660-1662.
121. O'Loughlin A.J., Keogh A., Muller D.W. Insertion of a fenestrated Amplatzer atrial septostomy device for severe pulmonary hypertension. Heart Lung Circ 2006, 15(4):275-277.
122. Shitrit D., Amital A., Peled N., Raviv Y., Medalion B., Saute M., et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009, 23(2):178-183.
123. Massad M.G., Powell C.R., Kpodonu J., Tshibaka C., Hanhan Z., Snow N.J., et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005, 29(11):1510-1515.
124. Schachna L., Medsger T.A., Dauber J.H., Wigley F.M., Braunstein N.A., White B., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54(12):3954-3961.